Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia
This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib (BI 6727), a selective Polo-like kinase inhibitor. The primary endpoints were the maximum tolerated dose of volasertib and the incidence of do...
Spremljeno u:
| Glavni autori: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | engleski |
| Izdano: |
2015
|
| Online pristup: | https://doi.org/10.1111/cas.12814 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.12814 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|